A new systematic review suggests that fenofibrate may slow diabetic retinopathy after early eye disease is already present, but it did not show a clear benefit for preventing retinopathy before it begins.
This distinction matters. Fenofibrate is a prescription medicine traditionally used to lower triglycerides. It is not a substitute for glucose and blood-pressure management, regular retinal screening, eye injections, laser treatment or other specialist care. People should not start, stop or change fenofibrate after reading a research report.
Here is what the new evidence found, how it fits with the LENS randomized trial and what people with diabetes can reasonably discuss with their healthcare team.
Key takeaways
- The new review included 31 studies and separated prevention of new retinopathy from progression of established disease.
- Two randomized trials found no clear evidence that fenofibrate prevented retinopathy in people who did not already have it.
- Five randomized trials in people with established diabetic retinopathy suggested less overall progression and less progression to diabetic macular oedema.
- A separate randomized-trial-only meta-analysis also found slower structural progression, but did not establish that fenofibrate preserves visual acuity or visual function.
- Fenofibrate is not appropriate for everyone and requires a prescriber to consider kidney function, other medicines and potential adverse effects.
- Retinal screening remains essential even if someone is taking fenofibrate.
What is diabetic retinopathy?
Diabetic retinopathy occurs when diabetes damages the small blood vessels in the retina, the light-sensitive tissue at the back of the eye. Early changes often cause no symptoms, which is why retinal screening is important.
As the condition progresses, blood vessels can leak, close or grow abnormally. Diabetic macular oedema develops when fluid affects the macula, the part of the retina responsible for detailed central vision.
Good glucose and blood-pressure management can reduce risk, but they do not remove it completely. Depending on the stage, specialist treatment may include eye injections, laser treatment or surgery.
What did the new review examine?
The systematic review and meta-analysis, published in Survey of Ophthalmology, included 31 studies. The researchers deliberately separated two different questions:
- Does fenofibrate prevent diabetic retinopathy from developing?
- Does fenofibrate slow progression after diabetic retinopathy is already present?
This is clinically important because a medicine may have a different effect at different stages of a disease.
No clear evidence for primary prevention
For people without diabetic retinopathy at the start of a trial, the pooled result from two randomized trials showed no evidence of benefit. The odds ratio was 1.00, with a 95% confidence interval from 0.70 to 1.43.
An odds ratio of 1.00 means the groups had the same estimated odds in the analysis. The wide confidence interval means a modest benefit or harm could not be ruled out. The researchers rated this evidence as low certainty.
Therefore, the study does not support taking fenofibrate simply to prevent a first diagnosis of diabetic retinopathy.
A stronger signal after retinopathy is present
Among people who already had diabetic retinopathy, five randomized trials found that fenofibrate was associated with less progression:
- Overall retinopathy progression: odds ratio 0.56, with a 95% confidence interval from 0.42 to 0.74.
- Progression to diabetic macular oedema: odds ratio 0.52, with a 95% confidence interval from 0.36 to 0.74.
The researchers rated both findings as moderate-certainty evidence. These relative measures do not tell every individual how much their personal risk would change. Absolute benefit depends on the starting risk, type and severity of retinopathy, duration of follow-up and other health factors.
What did the randomized-trial-only evidence show?
A separate 2026 systematic review restricted its analysis to randomized trials and incorporated the LENS trial. Three completed trials, involving 3,756 participants, contributed to its main pooled outcome.
Fenofibrate was associated with a 23% relative reduction in structural retinopathy progression, with an estimated 45 fewer progression events per 1,000 people treated. The evidence was rated moderate certainty.
However, the same review found no trial evidence of improvement in visual acuity or visual function. Evidence concerning the need for modern retinal treatment was less certain, and evidence about macular oedema could not be pooled consistently.
This difference is crucial: slowing changes seen on retinal imaging is useful, but it is not the same as proving that a medicine prevents loss of sight.
How the LENS trial fits in
The Lowering Events in Non-Proliferative Retinopathy in Scotland trial, known as LENS, was designed specifically to test fenofibrate in adults with diabetes and early retinal changes.
A total of 1,151 participants were randomized. Over a median follow-up of four years, the primary outcome occurred in 22.7% of participants assigned fenofibrate and 29.2% assigned placebo. The hazard ratio was 0.73.
LENS also reported less progression of retinopathy or maculopathy and less development of macular oedema. It did not find an improvement in visual acuity, visual function or quality of life during the trial.
The study was conducted within Scotland’s national diabetic eye-screening program. Its results are important, but local screening systems, prescribing rules and approval of fenofibrate for eye disease vary between countries.
What is fenofibrate?
Fenofibrate belongs to a group of medicines called fibrates. It is commonly prescribed to treat high triglyceride levels and some mixed lipid disorders. Its possible retinal effect may not depend entirely on changes in cholesterol or triglycerides, but the exact protective mechanisms remain under investigation.
Fenofibrate is not a general eye vitamin and should not be bought or used without medical supervision. A prescriber needs to consider why it is being used, kidney function, other medicines, possible interactions and adverse effects.
What about safety?
The randomized-trial-only meta-analysis reported an increased rate of venous thromboembolism, meaning blood clots in a vein, with a risk ratio of 1.52. This estimate came entirely from one large older trial, FIELD, so it needs careful interpretation rather than alarm.
Like all prescription medicines, fenofibrate can cause adverse effects and is unsuitable for some people. Muscle symptoms, kidney-function changes and interactions with other lipid-lowering or anticoagulant medicines may require review. The balance of benefit and risk must be assessed for the individual.
Do not stop a currently prescribed medicine abruptly. Ask the prescriber or pharmacist if you have concerns.
What should people with diabetes do now?
The new evidence does not create a universal recommendation for everyone with diabetes. Practical next steps are:
- Attend retinal screening at the interval recommended for you, even if your vision seems normal.
- Work with your diabetes team on glucose and blood-pressure management.
- If early or established diabetic retinopathy has been diagnosed, ask whether the fenofibrate evidence is relevant to your situation and country.
- Tell the clinician about all medicines and supplements you take.
- Do not use fenofibrate as a replacement for retinal injections, laser treatment or specialist follow-up.
When to seek urgent eye care
Diabetic retinopathy can progress without symptoms, but sudden changes require prompt assessment. Seek urgent eye care for sudden loss of vision, a rapid increase in floaters, flashes of light, a dark curtain or shadow across the vision, or severe eye pain.
Important limitations
- The main review combined randomized and non-randomized studies, although the strongest conclusions were based on randomized trials.
- Only two randomized trials addressed primary prevention, and the result was imprecise.
- Definitions of retinopathy progression varied between trials.
- Most trial participants had type 2 diabetes; evidence specific to type 1 diabetes was limited.
- Structural retinal outcomes do not automatically translate into better visual acuity or quality of life.
- Some evidence about treatment requirements came from before anti-VEGF injections became standard practice.
- Country-specific licensing and clinical guidance may differ.
The bottom line
The newest evidence suggests that fenofibrate may slow progression in people who already have diabetic retinopathy, particularly early disease. It did not show a clear benefit for preventing retinopathy before it develops, and it has not been proven to improve vision.
This is a discussion to have with a diabetes clinician, eye specialist or prescriber. Fenofibrate should not be self-started, and it does not replace retinal screening, glucose and blood-pressure management, or specialist eye treatment.
Sources
- Yaldo L, et al. Effect of systemic fibrates on diabetic retinopathy prevention and progression: a comprehensive systematic review and meta-analysis. Survey of Ophthalmology. Published 23 September 2026. doi:10.1016/j.survophthal.2026.09.006.
- Bhandari M, et al. Effect of fenofibrate on diabetic retinopathy progression: an RCT-only systematic review and meta-analysis incorporating the LENS trial. Diabetes Research and Clinical Practice. 2026;241:113543.
- Preiss D, et al. Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial. Health Technology Assessment. 2026;30(41):1-70.
- National Eye Institute. Diabetic Retinopathy.
- MedlinePlus. Fenofibrate.
This article provides general education and is not individual medical advice. Do not start, stop or change fenofibrate, lipid treatment or diabetes treatment without speaking with a qualified healthcare professional.